Navigation Links
Cancer Research UK Offers New Hope To Cancer Patients

In a new clinical development partnership being launched by the Cancer Research UK, and its commercial arm, Cancer Research Technology (CRT) plans to take up// drug candidates that pharmaceuticals companies have ‘deprioritised’ for not showing enough commercial promise following their preclinical studies. By this they plan to develop new treatments from anti-cancer drugs that have been shelved by pharmaceutical and biotechnology companies.

Under the scheme, companies will hand over molecules that once showed promise, but were never developed, and CRT will take on the clinical trials for those molecules. It is proposed that the Pharma and biotech firms will keep the intellectual property rights to the molecules they had shelved. After CRT has done clinical trials, the company will be given the option to take the molecule back and develop it themselves, or to leave it in the hands of the CRT scientists.

Harpal Kumar CRT chief executive hopes that the scheme that would cost up to £2 million a year, will help to identify at least five more drug molecules annually, to add to CRT’s current portfolio of around 25 licensed molecules in the clinic.Kumar sounding very optimistic said that they Hopefully would be flooded with opportunities, he told reporters. Kumar was also keen to state a point that the project was not being developed as a money-spinner for the charity, but he said that the Cancer Research UK does expects to receive a share of any financial return made by the companies.

Richard Tiner, medical director of the Association of the British Pharmaceutical Industry (ABPI) said that he personally could saw no reason for the scheme to fail, but accepted that there could be legal hurdles surrounding intellectual property rights and contracts. He explained that inevitably when discussing business or IP issues there will be differences of opinion. The CRT has approached around 20 leading pharmaceutical and biotech companies, and is c lose to deals with three. Victoria John, head of licensing for the clinical development partnerships scheme, said that those three opportunities is very good at this stage.

Kumar explained that the nature of the scheme means that many of the drug candidates might be used for rare cancers, but this will not colour the decision about which drugs to develop. He explained that just because one type of cancer is common, it doesn’t mean it would get a higher priority than a rarer cancer.

ABPI’s Tiner predicts that other medical charities will be watching the process carefully.

'"/>




Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2017)... ... June 26, 2017 , ... Dr. Martin Bastuba, MD, FACS, ... with the Fertility Center of California, is pleased to announce the addition of ... and TESA (percutaneous testicular sperm extraction). These minimally invasive treatments are primarily used ...
(Date:6/26/2017)... ... 26, 2017 , ... If the devil is in the ... these days. According to recent estimates, 75 – 80% of the medical bills ... studies point to Electronic Health Records (EHR) with automated features designed to ease ...
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United States Senate on Thursday ... Better Care Reconciliation Act. It differs significantly from the American Health Care Act, which ... in committee, or the House will have to take up the Senate version as-is, ...
(Date:6/24/2017)... ... June 24, 2017 , ... Genes Advice, ... medications in select Florida and Texas doctors' offices and clinics. This breakthrough testing ... of genetic testing recognizes the role genes play in determining an individual's tolerance ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... announced the launch of Care Management Alerts and Dashboards, an innovative new service ... Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide near real-time data ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... ANGELES , June 8, 2017   Responding to ... drug oversight and the death of singer Chris Cornell ... on Human Rights International offers a free online ... better educate consumers and families about psychotropic drug risks. ... Ledger , who died from an accidental overdose, has called ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ... Joseph R. Goodwin , U.S. District Court Judge ... , entered a case management order in MDL ... Liability Litigation (the "MDL") that includes a provision requiring ... disclosures on specific causation within one hundred twenty (120) ...
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
Breaking Medicine Technology: